ACE2 News and Research

RSS

Study uses computational modeling of coronavirus spike proteins to examine dynamics responsible for immunogenicity and immune escape

A new study published on the bioRxiv* preprint server focused on the development of dynamic computational models for a large subset of S proteins of SARS-CoV, MERS-CoV, and SARS-CoV-2.

23 Aug 2021

A systematic review of in vitro studies evaluating the efficacy of mouth rinses on SARS-CoV-2

A new study aims to evaluate the current body of published in vitro research related to the efficacy of mouthwashes in preventing SARS-CoV-2 transmission.

20 Aug 2021

SARS-CoV-2 mutations alter dynamics of neutralizing antibodies

A new study describes how monoclonal antibodies raised against SARS-CoV-2 are affected by mutations in the antibody binding site.

20 Aug 2021

SARS-CoV-2 lambda variant escapes immune response via spike mutations

A new study explores the mechanism by which the SARS-CoV-2 lambda variant has acquired immune evasion capabilities above that of the wildtype.

20 Aug 2021

Study points to a novel strategy for developing broad-spectrum vaccines against coronaviruses

Scientists from Duke-NUS Medical School and the National Centre for Infectious Diseases (NCID) found that 2003 SARS survivors who have been vaccinated with the Pfizer-BioNTech mRNA vaccine produced highly potent functional antibodies that are capable of neutralizing not only all known SARS-CoV-2 variants of concerns (VOCs) but also other animal coronaviruses that have the potential to cause human infection.

20 Aug 2021

Researchers discover glycan 'gates' that open to allow SARS-CoV-2 entry

Since the early days of the COVID pandemic, scientists have aggressively pursued the secrets of the mechanisms that allow severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to enter and infect healthy human cells.

19 Aug 2021

SARS-CoV-2 antibodies found to neutralize bat coronavirus (RaTG13) in new study

A striking new study examines how far antibodies elicited by vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), or by natural infection, can neutralize the closely related bat coronavirus (CoV) RaTG13.

19 Aug 2021

How does the SARS-CoV-2 Delta variant’s spike drive membrane fusion and immunity evasion?

A fascinating and timely new study shows how the Delta variant of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) achieved higher transmissibility and resistance to neutralization.

19 Aug 2021

Durable highly protective T cell response to AAV-spike vaccine against COVID-19 pneumonia in mice

New research, available as a preprint on the bioRxiv* server, has focused on the role played by T cell immunity, particularly CD8+ cytotoxic T cells, on preventing lethal infection with SARS-CoV-2 in mice infused with peptide-loaded antigen-presenting dendritic cells (DCs).

19 Aug 2021

Scientists identify a potent neutralizing nanobody against SARS-CoV-1

In a recently published article in the journal Virologica Sinica, scientists have described the development and validation of a potent nanobody that targets the receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus (SARS-CoV). The nanobody efficiently and specifically blocks the interaction between RBD and angiotensin-converting enzyme 2 (ACE2) and neutralizes the virus.

19 Aug 2021

White-tailed deer are highly susceptible to SARS-CoV-2 infection

The SARS-CoV-2 virus has been shown to infect a wide range of animals naturally and experimentally, and prior studies indicate deer are susceptible to infection. White-tailed deer (Odocoileus virginianus) fawns have been found to be susceptible to SARS-CoV-2.

19 Aug 2021

Why have COVID-19 caseloads been comparatively low in Africa?

A new study has been published in the International Journal of Environmental Research and Public Health that highlights the potential lessons that the world can draw from Africa on assumptions concerning viral pandemics. This is particularly important, given Africa’s long experience with dangerous infectious diseases.

18 Aug 2021

Study examines prevalence of neutralizing antibodies to HCoV-NL63 in healthy adults in Australia

A new study has been published in the MPDI journal Viruses, which focuses on determining the seroprevalence of neutralizing antibodies against HCoV-NL63, in healthy adults, in a cross-sectional study.

18 Aug 2021

How do glycans affect SARS-CoV-2 spike protein openings?

In a paper recently uploaded to the bioRxiv* preprint server, the role of glycan coating on the SARS-CoV-2 spike protein is further investigated by molecular dynamics simulations of the glycosylated and non-glycosylated protein, identifying several key glycans that play a role in stabilizing and protecting the RBD, and also encourage bonding with the ACE2 receptor.

18 Aug 2021

Increased chemosensory dysfunction with D614G mutation of SARS-CoV-2

A study, available on the pre-print server medRxiv, has determined the underlying molecular mechanisms of how severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), especially the G614 strain, leads to olfactory dysfunction causing anosmia.

18 Aug 2021

P681R spike mutation enhances replication efficiency of SARS-CoV-2 delta variant

A team of scientists from the University of Texas, USA, has recently revealed that the P681R spike mutation is responsible for increased infectivity of the delta variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The P681R spike mutation increases the replication of the delta variant by increasing the dissociation of S1 and S2 subunits at the furin cleavage site. The study is currently available on the bioRxiv* preprint server.

18 Aug 2021

Data reinforces SAB-185’s potential to neutralize SARS-CoV-2 variants

A study, available on the pre-print server bioRxiv*, evaluated the neutralizing capacity of a fully human polyclonal antibody (SAB-185) against the Delta, Kappa, and Lambda variants using a lentiviral-based pseudovirus assay.

17 Aug 2021

How delta and kappa variants of SARS-CoV-2 evade the immune system

A new study, available on the bioRxiv* preprint server, describes the neutralizing ability of the monoclonal antibodies against the variants and the difference of the ACE2 binding affinity found in the variants.

17 Aug 2021

In Southeast Asia, robust immunity found up to 9 months after SARS-CoV-2 infection

Now, a new study posted to the bioRxiv* preprint server focuses on functional immune memory to SARS-CoV-2, up to nine months in a Southeast Asian cohort, in the absence of re-infection.

16 Aug 2021

Vaccinating previously infected induces more potent antibodies less susceptible to escape from SARS-CoV-2 variants

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the causal agent of the coronavirus disease 2019 (COVID-19) pandemic, which has claimed more than 4.3 million lives worldwide. Even after implementing various measures, such as vaccination and social restrictions, SARS-CoV-2 and its variants of concern (VoC) leave the world's public health systems and economies in turmoil.

16 Aug 2021

ACE2 News and Research

Study uses computational modeling of coronavirus spike proteins to examine dynamics responsible for immunogenicity and immune escape

A systematic review of in vitro studies evaluating the efficacy of mouth rinses on SARS-CoV-2

SARS-CoV-2 mutations alter dynamics of neutralizing antibodies

SARS-CoV-2 lambda variant escapes immune response via spike mutations

Study points to a novel strategy for developing broad-spectrum vaccines against coronaviruses

Researchers discover glycan 'gates' that open to allow SARS-CoV-2 entry

SARS-CoV-2 antibodies found to neutralize bat coronavirus (RaTG13) in new study

How does the SARS-CoV-2 Delta variant’s spike drive membrane fusion and immunity evasion?

Durable highly protective T cell response to AAV-spike vaccine against COVID-19 pneumonia in mice

Scientists identify a potent neutralizing nanobody against SARS-CoV-1

White-tailed deer are highly susceptible to SARS-CoV-2 infection

Why have COVID-19 caseloads been comparatively low in Africa?

Study examines prevalence of neutralizing antibodies to HCoV-NL63 in healthy adults in Australia

How do glycans affect SARS-CoV-2 spike protein openings?

Increased chemosensory dysfunction with D614G mutation of SARS-CoV-2

P681R spike mutation enhances replication efficiency of SARS-CoV-2 delta variant

Data reinforces SAB-185’s potential to neutralize SARS-CoV-2 variants

How delta and kappa variants of SARS-CoV-2 evade the immune system

In Southeast Asia, robust immunity found up to 9 months after SARS-CoV-2 infection

Vaccinating previously infected induces more potent antibodies less susceptible to escape from SARS-CoV-2 variants

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News